KOOL on nasdaq had nice open so far...30k in 10 min...just below #:
THERMOGENESIS CORP. Places Fourth BioArchive System With the New York Blood Center
Clinical success of placental cord blood (``PCB'') stem cell transplants justify need for expanded inventory
RANCHO CORDOVA, Calif.--(BUSINESS WIRE)--Jan. 3, 2001-- THERMOGENESIS CORP. (Nasdaq:KOOL - news) announced the sale of a fourth BioArchive® System to the New York Blood Center (``NYBC''), which is collecting an inventory of 50,000 ethnically diverse PCB units to better serve the patients who suffer from diseases such as leukemias, lymphomas, diverse inherited anemias and hypoproliferative stem cell disorders. Phil Coelho, CEO of THERMOGENESIS CORP., noted that ``... at the December 2000 American Society of Hematology (''ASH``) conference, Dr. Pablo Rubinstein of NYBC analyzed the results of their 1,100 transplants and confirmed that better HLA matching of the PCB unit to the patient significantly improves patient outcome. Better matches can only be achieved through larger inventories of high quality cryopreserved PCB units.''
Each BioArchive System is used by NYBC to process, cryopreserve and archive up to 3,626 PCB stem cell units. BioArchive Systems have also been chosen by the major Cord Blood Banks in Japan, China, Taiwan, Vietnam, Korea, Germany, Spain, Finland, U.K., Belgium, Mexico, as well as in the U.S.A. pursuant to Investigational New Drug (``IND'') regulations. The BioArchive System is demonstrably the international standard for processing and archiving cryopreserved hematopoietic stem cells.
Phil Coelho further noted that ``... recent research suggests that there are uncommitted or ''neutral`` stem cells that can be induced to produce other cells outside the hematopoietic system such as neural or hepatic cells. With the recent bio-ethical issues raised regarding embryonic stem cell research, cord blood may provide a source of stem cells for tissue regeneration without the ethical issues involved with embryos or fetuses. The greater the interest in this type of cellular therapy research, the greater potential we have for additional unit sales.''
About the BioArchive System
The BioArchive System uses THERMOGENESIS CORP.'s proprietary computer-driven liquid nitrogen robotic system to cryopreserve and archive units of blood components that have been collected, processed and preserved in proprietary sterile plastic bag sets. The BioArchive System tracks identification and location for each unit and performs robotic retrieval of each unique tissue-typed unit for use. The BioArchive System operates to freeze, place and retrieve samples without exposing other archived samples to detrimental temperature changes.
The BioArchive System is a Class II exempt blood component freezer, and has initially been distributed in the U.S. only to institutions operating under FDA IND exemptions to provide PCB stem cell units for transplant. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include peripheral blood-derived stem-cells, cell lines, cancer vaccines, male sperm cells, female eggs, heart valves, corneas, virus samples, biopsy samples and other cellular therapy products.
THERMOGENESIS CORP. BioArchive System is currently intended for preservation of blood components and blood products and would require FDA approval or clearance for some additional claims.
About New York Blood Center
The NYBC is the country's largest independent blood center and a world leader in biomedical research. The NYBC Placental Blood Program has pioneered the use of PCB as a source of stem cells for bone marrow restoration for such diseases as leukemia or inherited or acquired diseases of the blood and immune systems. The Placental Blood Program has collected more than 12,000 PCB donations and provided units for approximately 1,000 transplants since 1993.
About THERMOGENESIS CORP.
THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and distributing equipment to collect, cryopreserve and archive highly sensitive blood products and biological tissue for more than 10 years.
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Contact:
THERMOGENESIS CORP.
James H. Godsey, Ph.D., 916/858-5100
jgodsey@thermogenesis.com
www.thermogenesis.com
Email this story - Most-emailed articles - Most-viewed articles |
